Literature DB >> 14513285

Proinflammatory syndrome mimicking acute rheumatoid arthritis in a patient with Waldenstrom's macroglobulinemia treated with rituximab.

E M Buda-Okreglak1, J J Drabick, N R Delaney.   

Abstract

Acute adverse reactions to rituximab treatment have been previously described in association with initiation of therapy. We describe a novel delayed proinflammatory syndrome which occurred at, or near, the completion of a 4-week dose-intense course with rituximab in a 58-year-old man with Waldenstrom's macroglobulinemia, and which mimicked acute rheumatoid arthritis affecting the hands and the knees. This syndrome was associated with an increase in acute phase reactants, and the clinical symptoms were temporally reproducible, although decreased in severity, with subsequent rituximab therapy, and each time responded to prednisone. This is the first report on an acute rheumatoid-like flare occurring in association with rituximab therapy. This phenomenon is all the more intriguing in that rituximab has been used to treat refractory rheumatoid arthritis. Potential etiologic mechanisms and management of this newly described phenomenon are discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14513285     DOI: 10.1007/s00277-003-0747-5

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  4 in total

1.  Guillain-Barre syndrome in a patient with diffuse large B-cell lymphoma, and rituximab maintenance therapy. An association beyond anecdotal evidence?

Authors:  Alberto Carmona; Juan Domingo Alonso; Manuel de las Heras; Agustín Navarrete
Journal:  Clin Transl Oncol       Date:  2006-10       Impact factor: 3.405

2.  Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome.

Authors:  Alice Bonanni; Marta Calatroni; Matteo D'Alessandro; Sara Signa; Enrica Bertelli; Michela Cioni; Eddi Di Marco; Roberto Biassoni; Gianluca Caridi; Giulia Ingrasciotta; Roberta Bertelli; Armando Di Donato; Maurizio Bruschi; Alberto Canepa; Giorgio Piaggio; Pietro Ravani; Gian Marco Ghiggeri
Journal:  Br J Clin Pharmacol       Date:  2018-03-25       Impact factor: 4.335

3.  A 57-year-old man who developed arthritis during R-CHOP chemotherapy for non-Hodgkin lymphoma.

Authors:  F H Swaneveld; R M van Vugt; J P de Boer; B A C Dijkmans; W F Lems
Journal:  Clin Rheumatol       Date:  2007-07-28       Impact factor: 2.980

Review 4.  Novel applications of Rituximab in dermatological disorders.

Authors:  Prasan R Bhandari; Varadraj V Pai
Journal:  Indian Dermatol Online J       Date:  2014-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.